Treatment of Overactive Bladder in the Frail Patient

被引:0
|
作者
Vincent, Sage [1 ]
Tokarski, Anthony [1 ]
Murphy, Alana [1 ]
机构
[1] Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Dept Urol, Philadelphia, PA 19107 USA
关键词
Overactive bladder; Frailty; Risk assessment; Cognitive impairment; QUALITY-OF-LIFE; URINARY-INCONTINENCE; COGNITIVE FUNCTION; AMERICAN-COLLEGE; INCREASED RISK; IMPACT; PREVALENCE; DETRUSOR; SYMPTOMS; ANTICHOLINERGICS;
D O I
10.1007/s11884-020-00621-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of Review To understand how frailty interacts with overactive bladder. To explore how frailty should be considered when devising an individualized treatment plan for OAB patients. Recent Findings Frailty can be assessed in the outpatient office without undue burden. The urology community is increasingly aware of the importance of evaluating a patient for frailty and including this assessment in treatment algorithms. Frailty should be considered when treating OAB patients, since frail OAB patients are more susceptible to the potential deleterious consequences of medical therapy, onabotulinumtoxinA therapy, and sacral neuromodulation. A patient's frailty status should be considered during counseling regarding OAB therapy. Additional studies are needed to examine the treatment effects and risks in the frail OAB population.
引用
收藏
页码:386 / 392
页数:7
相关论文
共 50 条
  • [41] MIRABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER
    Gras, J.
    DRUGS OF TODAY, 2012, 48 (01) : 25 - 32
  • [42] Antimuscarinics for treatment of overactive bladder
    Andersson, KE
    LANCET NEUROLOGY, 2004, 3 (01): : 46 - 53
  • [43] Under Treatment of Overactive Bladder
    Ballert, Katie N.
    JOURNAL OF UROLOGY, 2010, 183 (04): : 1282 - 1283
  • [44] Patient persistency with medications for overactive bladder
    Chui, MA
    Williamson, T
    Arciniega, J
    Thompson, C
    Benecke, H
    VALUE IN HEALTH, 2004, 7 (03) : 366 - 366
  • [45] Imidafenacin for the treatment of overactive bladder
    Maggiore, Umberto Leone Roberti
    Scala, Carolina
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1383 - 1397
  • [46] Diagnosis and treatment of the overactive bladder
    Wein, AJ
    UROLOGY, 2003, 62 (5B) : 20 - 27
  • [47] AbobotulinumtoxinA for the treatment of overactive bladder
    Flint, Richard
    Rantell, Angie
    Cardozo, Linda
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1005 - 1013
  • [48] Tolterodine for treatment of overactive bladder
    Kanofsky, Jamie A.
    Nitti, Victor W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2006, 33 (04) : 447 - +
  • [49] Patient frailty and the burden of overactive bladder
    Athavale, A.
    Gooch, K.
    Walker, D. R.
    Suh, M.
    Scaife, J.
    Haber, A.
    Hadker, N.
    Dmochowski, R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 : S86 - S86
  • [50] Onabotulinumtoxin A for the treatment of overactive bladder
    Cox, Lindsey
    Cameron, Anne P.
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 79 - 89